Anish Patel Biography and Net Worth

Co-founder and Chief Operating Officer of Enliven Therapeutics

Anish is a co-founder of Enliven Therapeutics and serves as the Chief Operating Officer. Prior to co-founding Enliven, Anish was the Head of Medical Affairs at AbbVie Stemcentrx, where he was responsible for building external collaborations and driving early oncology programs towards clinical proof-of-concept.

Previously, Anish contributed to the buildout of commercial and medical affairs capabilities, at Pharmacyclics for Imbruvica^® (ibrutinib), culminating in the company’s acquisition by AbbVie for $21B. Anish has also held leadership roles at MedImmune/AstraZeneca and Berlex/Bayer.

Anish earned a Pharm.D. from the University of Michigan, Ann Arbor and a B.S. in Microbiology and Chemistry from the University of Illinois, Urbana-Champaign.

What is Anish Patel's net worth?: The estimated net worth of Anish Patel is at least $5.86 million as of April 7th, 2025. Mr. Patel owns 316,643 shares of Enliven Therapeutics stock worth more than $5,857,262 as of April 24th. This net worth estimate does not reflect any other assets that Mr. Patel may own. Learn More about Anish Patel's net worth.
How old is Anish Patel?: Mr. Patel is currently 43 years old. There are 5 older executives and no younger executives at Enliven Therapeutics. The oldest executive at Enliven Therapeutics is Dr. Helen Louise Collins M.D., Chief Medical Officer, who is 61 years old. Learn More on Anish Patel's age.
How do I contact Anish Patel?: The corporate mailing address for Mr. Patel and other Enliven Therapeutics executives is 309 Beacon Street Suite 300 Office 341, Brookline MA, 02446. Enliven Therapeutics can also be reached via phone at 617-927-9989 and via email at ir@imaratx.com. Learn More on Anish Patel's contact information.
Has Anish Patel been buying or selling shares of Enliven Therapeutics?: During the last quarter, Anish Patel has sold $120,272.68 in Enliven Therapeutics stock. Most recently, Anish Patel sold 6,667 shares of the business's stock in a transaction on Monday, April 7th. The shares were sold at an average price of $18.04, for a transaction totalling $120,272.68. Following the completion of the sale, the chief operating officer now directly owns 316,643 shares of the company's stock, valued at $5,712,239.72. Learn More on Anish Patel's trading history.
Who are Enliven Therapeutics' active insiders?: Enliven Therapeutics' insider roster includes Rahul Ballal (Director), Rishi Gupta (Director), Richard Heyman (Chairman of the Board of Directors), Benjamin Hohl (Chief Financial Officer and Head of Corporate Development), Samuel Kintz (Co-founder, Chief Executive Officer, and Member of the Board of Directors), Joseph Lyssikatos (Co-founder, Chief Scientific Officer), and Anish Patel (Co-founder and Chief Operating Officer). Learn More on Enliven Therapeutics' active insiders.
Are insiders buying or selling shares of Enliven Therapeutics?: In the last twelve months, insiders at the sold shares 67 times. They sold a total of 1,443,876 shares worth more than $32,811,792.39. The most recent insider tranaction occured on April, 21st when insider Joseph P Lyssikatos sold 5,000 shares worth more than $80,350.00. Insiders at Enliven Therapeutics own 29.2% of the company. Learn More about insider trades at Enliven Therapeutics.
Information on this page was last updated on 4/21/2025.

Anish Patel Insider Trading History at Enliven Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/7/2025	Sell	6,667	$18.04	$120,272.68	316,643
3/7/2025	Sell	6,667	$21.44	$142,940.48	323,310
2/7/2025	Sell	6,667	$21.93	$146,207.31	329,977
1/7/2025	Sell	21,700	$24.18	$524,706.00
10/18/2024	Sell	716	$30.00	$21,480.00	343,311
7/15/2024	Sell	30,978	$25.05	$775,998.90	345,574
7/12/2024	Sell	17,475	$25.07	$438,098.25	376,552
6/6/2024	Sell	1,133	$20.06	$22,727.98
5/14/2024	Sell	1,107	$25.00	$27,675.00
5/9/2024	Sell	260	$25.06	$6,515.60
5/6/2024	Sell	4,875	$22.72	$110,760.00
4/11/2024	Sell	17,500	$25.03	$438,025.00
4/8/2024	Sell	4,875	$18.60	$90,675.00	2,597
3/6/2024	Sell	4,875	$15.64	$76,245.00	7,472
2/6/2024	Sell	4,875	$15.11	$73,661.25	12,347
1/22/2024	Sell	4,875	$15.13	$73,758.75	17,222
1/2/2024	Sell	11,000	$15.00	$165,000.00	22,097
12/26/2023	Sell	102	$15.01	$1,531.02	35,637
12/22/2023	Sell	983	$15.03	$14,774.49	35,739

Anish Patel Buying and Selling Activity at Enliven Therapeutics

Enliven Therapeutics Company Overview

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.

Today's Range

Now: $18.30

$17.36

$18.57

50 Day Range

MA: $19.51

$14.91

$22.46

2 Week Range

Now: $18.30

$13.30

$30.03

Volume

249,987 shs

Average Volume

264,598 shs

Market Capitalization

$896.77 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.03

Anish Patel Biography and Net Worth

What is Anish Patel's net worth?

How old is Anish Patel?

How do I contact Anish Patel?

Has Anish Patel been buying or selling shares of Enliven Therapeutics?

Who are Enliven Therapeutics' active insiders?

Are insiders buying or selling shares of Enliven Therapeutics?